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Methods—Published studies on lung toxicity in patients with early stage non-small cell lung 
cancer (NSCLC) or metastatic lung tumors treated with SBRT were pooled and analyzed. The 
primary endpoint was RILT including pneumonitis and fibrosis. Data of RILT and risk factors 
were extracted from each study, and rates of grade 2-5 (G2+) and grade 3-5 (G3+) RILT were 
computed. Patient, tumor and dosimetric factors were analyzed for their correlation with RILT.
Results—Eighty-eight studies (7752 patients), that reported RILT incidence, were eligible. The 
pooled rates of G2+ and G3+ RILT from all 88 studies were 9.1% (95% CI: 7.15-11.4) and 1.8% 
(95% CI: 1.3-2.5), respectively. The median of median tumor sizes was 2.3 (range 1.4-4.1) cm. 
Among the factors analyzed, older patient age (P= 0.044) and larger tumor size (the greatest 
diameter) were significantly correlated with higher rates of G2+ (P= 0.049) and G3+ RILT (P= 
0.001). Patients with stage IA vs. stage IB NSCLC had significantly lower risks of G2+ RILT 
(8.3% vs 17.1%, OR= 0.43, 95% CI: 0.29-0.64, P<0.0001). Among studies that provided detailed 
dosimetric data, the pooled analysis demonstrated a significantly higher mean lung dose (MLD) 
(P= 0.027) and V20 (P= 0.019) in patients with G2+ RILT comparing to that of grade 0-1 RILT.
Conclusions—The overall rate of RILT is relatively low after thoracic SBRT. Older age and 
larger tumor size are significant adverse risk factors for RILT. Lung dosimetry, specifically lung 
V20 and MLD also significantly affect RILT risk.
Summary—Risk factors for radiation-induced lung toxicity (RILT) after stereotactic body 
radiotherapy (SBRT) were analyzed from 88 published studies (7752 patients). The overall rate of 
RILT is relatively low after thoracic SBRT. Adverse risk factors for RILT after SBRT include older 
age, larger tumor size and greater lung dose-volume exposure as measured by mean lung dose and 
volume of lung receiving greater than 20 Gy.
Introduction
Stereotactic body radiotherapy (SBRT) is the standard of care for patients with medically 
inoperable stage I non-small cell lung cancer (NSCLC) (1). For operable early stage NSCLC 
patients, a meta-analysis (2) of 11921 patients in 63 studies demonstrated that overall 
survival or disease-free survival did not differ significantly between SBRT and surgery when 
patients' baseline condition was comparable. Recent studies (3-8) have demonstrated 
effectiveness of SBRT for oligometastasis(es) (1-5 pulmonary nodules).
Radiation induced lung toxicities (RILT), including radiation pneumonitis (RP) and clinical 
lung fibrosis, are important dose limiting toxicities. From published data to date, the rate of 
symptomatic RP ranged from 0% to 49% (9-12); the rate of radiation-induced lung fibrosis, 
which can continue to evolve beyond one year after SBRT, is reportedly up to 70-80% in 
high-dose regions (13), albeit most often asymptomatic. Fatal (grade 5) RILT after SBRT 
warrants serious consideration although is only sporadically reported (14).
Many factors, including patient-related, tumor-related and dosimetric may play important 
roles in the risk of RILT (15). SBRT dose and fractionation are often considered important, 
affecting clinical management decisions with respect to lung tolerance and tumor control, 
particularly in elderly patients and/or those with chronic lung interstitial diseases (12,16). 
Physical dosimetric measures such as mean lung dose (MLD) and lung V20 (percent or 
absolute volume receiving over 20 Gy), often used to guide clinical practice, were analyzed 
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in some studies, showing inconsistent relationship with RILT after SBRT (17-19), perhaps 
due to the limited number of toxicity events from each study.
Here we aimed to examine the risk of RILT after thoracic SBRT from the published studies 
to date and to study the significance of clinical and simple dosimetric risk factors in relation 
to RILT.
Materials and Methods
Selection criteria
Eligible studies included those that described treatment with SBRT either for primary 
NSCLC or metastatic lung tumors. Detailed reporting of RILT, including rate and grade, 
after SBRT was required. Studies of patients who received radiotherapy prior to SBRT, 
SBRT in conjunction with systemic therapy, and/or SBRT as a boost therapy after 
conventional radiotherapy were excluded. Publications were limited to those written in 
English.
Search methods
Studies published before Dec 2014 were sought by electronic databases (PubMed, Embase 
and Cochrane), using the search terms of lung tumor/cancer, SBRT/SABR and lung toxicity/
pneumonitis/lung fibrosis. When there was uncertainty about the eligibility of a study, the 
decision was made by the first and senior authors.
Data collection and calculation
The data collected for analysis included the number of patients and lesions, 14 clinical 
factors including age, gender, histology, stage, smoking status, tumor location, tumor size 
(maximum diameter of the tumor), gross tumor volume (GTV), planning target volume 
(PTV), total prescription dose, number of fractions, MLD and V20 for bilateral or ipsilateral 
lung, and prescribed biological effective dose with α/β= 10 (BED10). Male/female patients 
(M/F) ratio, centrally/peripherally located tumor ratio, the percentage of clinical stage I 
NSCLC, current smoking and percent of adenocarcinoma tumor were calculated. RILT data 
from grade 0 to grade 5 after treatment were also extracted, and data of RILT including 
grade 2-5 (G2+) and grade 3-5 (G3+) were summed from studies with such data provided.
Statistical analysis
To minimize potential bias due to heterogeneity, a pooled estimate for RILT rate was 
obtained using a Bayesian hierarchical model. The number of cases of RILT for each study 
were modeled with the binomial distribution with the logits of the binomial probabilities for 
each study following a normal distribution with mean and variance τ. These parameters had 
normal and inverse gamma priors, respectively. The overall rates of RILT and credible 
intervals were estimated as the posterior mean of μ. To compare the difference between 
asymptomatic (grade 0-1) and symptomatic (grade 2-5) RILT, odds ratio (OR) and 95% CI 
were estimated; P values were determined using the Chi-square test. χ2 tests and I2 were 
used to study heterogeneity between trials which represented the percentage of total 
variation across studies that was attributable to heterogeneity rather than to chance. If the 
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test indicated heterogeneity across studies (p<0.10 or I2>50%, the random effects model 
(Der Simonian-Laird method) was selected. Otherwise, we used the fixed effects model 
(Mantel-Haenszel method) to analyze relations between toxicity groups (20). Analyses were 
carried out using Revman 5.2 software. All tests were two-sided, and a p-value <0.05 was 
considered statistically significant.
Results
Patients and study characteristics
A total of 329 studies were identified at the initial search including all studies of SBRT for 
lung tumors; 241 studies were excluded due to 1) RILT data missing, 2) duplications of 
publication or publications with overlapping data, 3) prior thoracic radiation treatments with 
or without concurrent chemotherapy, or 4) non-original publications such as meta-analysis, 
review or case reports. Eighty-eight original studies including 7752 patients were eligible for 
this analysis (Fig 1 shows the detailed study selection). Pooled data of 14 clinical factors are 
shown in Tables 1 and 2. As not all the studies provided all elements of this study, numbers 
of study and patients varied such individual data provided for specific factors
Overall rates of RILT
Of all 88 studies, the Bayesian hierarchical model estimates of RILT were 9.1% (95% CI: 
7.15-11.4) and 1.8% (95% CI: 1.3-2.5), for G2+ and G3+ RILT, respectively. The crude rates 
and patient numbers with all RILT grades are shown in Fig 2A.
Fifty-four focused on primary lung cancers, 15 on lung metastases, and the remaining 19 on 
mixed patient populations. The average rates of G2+ RILT were 10.4% (95% CI: 9.8-15.2), 
7.0% (95% CI: 4.3-18.9) and 12.8% (95% CI: 7.8-22.2), respectively. The average rates of 
G3+ RILT were 2.2% (95% CI: 2.4-4.9), 1.6% (95% CI: 1.0-7.2), and 3.0% (95% CI: 
1.9-7.0), respectively. There was no significant difference in the RILT rates between patients 
with primary lung cancers and lung metastases from various primary sites (Fig 2B-C). This 
study thus analyzed the data without separating primary lung cancer and lung-metastatic 
patients.
Among these studies, 77 reported RP, 25 on lung fibrosis (of which 15 included detailed 
grading). From studies that provided detailed data, the average rates of G2+ / G3+ RP were 
9.5% (95% CI:7.8-11.3) / 2.2% (95% CI:1.7-3.1) (Fig D), and the average rates of G2+ / 
G3+ lung fibrosis were 0.2% (95% CI: 0.008-4.7) / 0.2% (95% CI:0.005-1.3) (Fig E). 
Unless otherwise specified, all RILT refer to either RP or fibrosis, or both.
Patient and tumor factors and RILT
Older patient age was significantly associated with higher rate of G2+ RILT (P= 0.045). 
Histology, tumor location (central versus peripheral), GTV and PTV were not significant. 
However, the largest tumor linear dimension was significant: studies with larger median 
tumor sizes had higher rates of G2+ (P= 0.049) and G3+ (P= 0.001) RILT (Fig 3A-F).
Selected clinical factors were compared between asymptomatic (grade 0-1) and 
symptomatic RILT (grade 2-5). In 6 studies of 1009 patients with stage IA (663 patients) or 
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IB (346 patients) NSCLC, 55 (8.3%, CI: 5.08-10.43) and 59 patients (17.1%, CI: 
11.34-23.52) had G2+ RILT, respectively. The odds ratio was 0.40 (CI: 0.26-0.63, 
P<0.0001). There was no significant heterogeneity with an I2 value of 0% (P= 0.66). There 
was no significant difference in gender for G2+ RILT, with rates of 10.5% (CI: 9.12-12.35) 
and 12.0% (CI: 7.7-17.42) in male and female patients, respectively (OR= 0.82, CI: 
0.49-1.37, P= 0.44). Tumor location was not significant: 38 in 318 (11.9%, CI: 7.73-23.59) 
patients with centrally located tumors developed G2+ RILT after SBRT, comparing to 
101/1005 (10.0%, CI: 10.64-18.30) patients with peripherally ones (OR= 1.14, CI: 
0.65-1.99, P= 0.65) (Fig 3G-I). There were insufficient separated results for G3+RILT to 
perform a meaningful analysis.
Simple dosimetric factors and RILT
Simple dosimetric factors including prescription BED10, MLD and V20 were reported in 67 
(6170 patients), 14 (1705 patients) and 19 (1928 patients) studies, resepctively. There were 
no significant correlations between the rates of G2+ and G3+ of RILT and median values of 
BED10, MLD, and V20. Data from each study were shown in Fig 4A-C.
A detailed breakdown of RILT by toxicity grade as a function of MLD was provided in only 
6 studies (599 patients). In these reports, ‘lung’ was defined as the anatomical structure with 
GTV or CTV removed. Two of these studies (119 patients) (10,21) reported a significant 
correlation after the linear-quadratic (LQ) correction of the mean ipsilateral lung dose. Four 
studies (480 patients) (11,17,22,23) reported significant correlation between symptomatic 
RILT and the mean total lung dose, without LQ correction. After approximating the data of 
ipsilateral MLD to whole lung MLD (divide ipsilateral MLD by two), the MLD in patients 
with G2+ RP was significantly greater than those without (5.9 Gy vs 4.1 Gy, P= 0.027) (Fig 
4D-E).
Five studies (595 patients) with detailed breakdown of RILT data were eligible for analysis 
of lung V20 between patients with G0-1 and G2+ RILT. In these studies, ‘lung’ was also 
defined as the anatomical structure of whole lung with GTV or PTV subtracted. Patients 
with G2+ RILT had significantly higher lung V20 than those with G0-1 RILT (6.2% vs 
4.7%, P= 0.019) (Fig 4F).
Discussion
This is a pooled analysis of 88 published studies (7752 patients) for lung toxicity and risk 
assessment after lung SBRT. The overall estimated rate of 9.1% for G2+ RILT was 
acceptably low. Older age, larger tumor, stage IB (vs IA) NSCLC, MLD and V20 were 
significant factors for higher risk of symptomatic toxicity, while gender, prescription dose 
and dose-fractionation were not. To our knowledge, this is the first pooled analysis of lung 
toxicities after lung SBRT. Although the pooled rate of G2+ RILT was low, it is necessary to 
consider reported study population and complex patient-specific factors in designing 
treatments to avoid severe adverse events in clinical practice. Lack of significant correlation 
in this study does not ensure safe practice in the clinic. For instance, although central 
location was not significantly correlated with RILT risks in this pooled analysis, other 
toxicities such as those of bronchus and esophagus can limit the ability to escalate dose to 
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central tumors (24-26). Additionally, for central lung tumors, the number of patients treated 
and cumulative experience of radiation oncologists and physicists are relatively limited. In 
two studies, RILT rates were relatively high after moderate-dose SBRT to larger or centrally 
located lesions (27,28). For patients with severe COPD, the RP rate after a total dose of 
40-50 Gy/5fx was relatively limited in Takeda's study (23.4% and 4.9% for G2+ and G3+ 
RP); however, the authors pointed out that this does not assure that SBRT is tolerable for all 
patients, and that pulmonary function, tumor location, interstitial lung diseases and other 
factors should be carefully considered before prescribing SBRT (29), consistent with 
recommendations from Yamashita et al (30,31).
It is expected that tumor size would be an important risk factor for RILT. Interestingly, our 
study showed significant correlation of RILT with the greatest tumor dimension, but not 
GTV or PTV. The pooled rate of G2+RILT was 17.1% in stage IB versus 8.3% in stage IA. 
Cuaron et al. reported 19.3% G2+ acute pulmonary toxicity in 63 patients with primary lung 
tumors >3 cm (28). Kanemoto et al. (32) reported significantly higher rate of G2+ RP for 
larger tumors vs. smaller ones (16.7% vs. 10.9%, P= 0.031) in 231 patients. Allibha et al. 
also reported (15) a significant difference in G2+ RP between larger and smaller tumors 
(17.9% vs 4.4%, P= 0.02) in a study of 185 patients. It is unclear to us why tumor volume 
(GTV and PTV) as continuous variables were not significantly associated with RILT while 
tumor size was a significant factor. This inconsistency may be partially explained by: 1) 
limited studies (22 studies for GTV and 36 studies for PTV) provided such data, and 2) the 
potential incremental effect of target volume (i.e. per cc) on RILT may be confounded by 
variation in the approach to delineating GTV i.e. use of breath-hold or free breathing CT 
scans, use of a single phase of 4DCT scan, or utilizing metabolic volume from PET. This 
suggests that SBRT with large-sized tumors (>3 cm) is most likely associated with higher 
risk of RILT, and should be done with careful consideration of lung dosimetry.
Prescription BED10, which accounts for both total dose and number of fractions of the 
tumor, is often used as a factor to evaluate safety for SBRT. This pooled analysis did not 
show a significant correlation of BED10 with either G2+ or G3+ RILT. This may be partially 
explained by the fact that here, BED10 specifically represents the dose to tumor instead of 
the normal lung, which has α/β of 3-4 Gy (33,34), which would generate different values of 
BED. Further, for highly conformal SBRT, the prescription dose does not necessarily 
correlate with the dose distribution in normal lung, which depends upon target volume, 
location and conformity. This is also supported by findings of a few individual reports for 
peripheral (35,36) and centrally located diseases (37).
MLD is a frequently used evaluation metric for radiotherapy treatment plans. Our findings 
that median MLD was not significant for RILT after SBRT at the pooled study level may be 
partially explained by several factors: 1) the wide variation of MLD within a study (i.e. a 
relatively low study median MLD will not account for individual patients with a high MLD); 
2) many factors may have confounded the reported MLD, including but not limited to: a) the 
use of homogeneous unit density dose calculations or the use of different tissue 
heterogeneity correction algorithms, b) inconsistent lung volume definitions (the whole lung 
volume minus GTV or PTV), lung from a free-breathing CT scan, a slow CT scan or 
minimum intensity projection, c) inconsistent target definition (GTV, CTV, ITV, PTV, and 
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type of CT scan used as described above), d) heterogeneous patient populations with various 
dose prescriptions (without LQ correlations), e) the biological effect of a given physical 
MLD can be expected to be very different when resulting from, e.g., prescriptions of 3×18 
Gy vs 5×9 Gy and 3) most studies lack individual patient data to adjust for these potential 
confounding factors. In fact, there was a significant difference in the MLD reporting 
methods in the 6 studies (10,11,17,21-23) that provided breakdown data in patients with 
G0-1 and G2-5 RILT. Ricardi et al. (10) and Guckenberger et al. (21) both reported the 
correlation of symptomatic RILT with the LQ corrected mean EQD2 of ipsilateral ‘lung-
CTV’. Guckenberger et al (20) estimated 0 to 11% symptomatic RILT at 8 Gy and 20% at 
approximately 14 Gy ipsilateral MLD, while Ricardi et al (9) reported a steeper dose-
response, rising from 0 to 20% complication rate over a range from 8 -16 Gy. Chang et al. 
(18,38) found a physical ipsilateral MLD of 10 Gy to be a significant cutoff point for G2+ 
RP on univariate analysis, while for bilateral lungs (with GTV or PTV subtracted), MLD of 
6 Gy was considered to be the significant cutoff. Takeda et al. (39,40) also reported that 
MLD was significant although no cutoff point was specified. While the current data do not 
provide enough evidence for us to set a safe limit for RILT, analogy to conventional 
fractionation leads us to expect that future studies will definitively identify MLD either of 
whole lung, or ipsilateral lung as a significant factor for RILT.
Similarly VDs, the percent or absolute volume of the lung or ipsilateral lung (minus targets 
as defined in the study) receiving more than dose (or biologically equivalent dose) D, are 
frequently used plan evaluation metrics but again evidence is limited in literature. V20 was 
not a significant factor at the study level in this pooled analysis, as discussed above. Again, 
treatments with the same V20 but delivered in different numbers of fractions can be 
expected to have different biological effects, so pooling this data may obscure any real 
effects. In a study of 263 tumors, Baker et al. reported a significant correlation of RILT with 
V5 and V10, where 86% of the treatments were 5 fractions (41). In Chang's study (18), after 
treating 82 patients with SBRT in 4 fractions, the authors found the cutoff points of 
V20<12% for bilateral lung-GTV and V30<15% for ipsilateral lung were significant 
predictors for G2+ RP on multivariate analysis. In an analysis of 133 tumors treated with 
SBRT in 5 fractions, Takeda et al. (42) reported that 15 Gy delivered to ≤6% of the bilateral 
lung-ITV resulted in a 5.4% rate of grade 2 RP vs. 32.2% for lung volumes > 6% (P= 
0.002), and high V15 was a significant factor differentiating between grade 0-1 and grade 2+ 
RP (HR= 1.275, 95% CI: 1.017-1.599, P= 0.035). However, in Yamashita's study (9) of 25 
cases treated with dose of 48 Gy in 4 fractions, RP was not significantly associated with 
MLD, V20, V30, V35, V40, V45, or V50, respectively.
The risk of symptomatic RILT after SBRT is apparently correlated with many factors, of 
which we analyzed fourteen frequently reported ones, yet almost none of these studies 
reported all these factors. Due to the limitations of the information provided in the published 
literature, this study is not sufficiently powerful to analyze all possible factors and provide 
concrete recommendation for safe clinical practice. We recommend future studies to provide 
more detailed data (e.g. DVHs, with patient specific clinical, outcome, and fraction number 
data), perhaps in electronic supplements, to allow more thorough analysis of factors involved 
in this important complication. Strengths of the current study include the large number of 
patients, allowing pooled analysis of RILT risks and relevant covariates. Limitations include 
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those inherent in retrospective analyses of data pooled from published studies, and are 
largely related to variability in treatment methodology and outcome reporting. Also, the 
relatively low rate of RILT could be confounded by publication bias in which a high rate of 
toxicity in any given patient cohort may be less likely to be reported.
Conclusions
This study demonstrates that SBRT for patients with lung tumors may be tolerated with 
overall modest rates of G2+ and G3+ RILT. Overall, age and tumor size as measured by the 
greatest dimension were significantly correlated with RILT. Higher MLD and V20 were 
significantly correlated with a higher rate of symptomatic RILT. Standardization of reporting 
for future studies should include risk factors such as patient, tumor, treatment and dosimetric 
details together with clearly defined RILT endpoints.
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Fig. 1. Study selection schema
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Fig. 2. RILT after SBRT
Plots show mean rates of RILT in all patients (A), primary and metastatic diseases separately 
(B-C), RP (D) and lung fibrosis (E). The number of patients differs from plot to plot, and 
point to point based on availability of such data. The comparison of RILT rates for primary 
and metastatic lung tumors are also shown and for G2+ (B) and G3+ RILT (C), when the 
horizontal bars show the Mean±95%CI values of RILT rate in each subgroup (B and C). 
SBRT= Stereotactic body radiation therapy, RILT = radiation induced lung toxicity, RP = 
radiation pneumonitis. RILT includes both RP and fibrosis.
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Fig. 3. Patient/tumor factors and RILT
Linear regression analysis were performed for all continuous variables. Representative plots 
are shown. RILT= radiation induced lung toxicity. G2+= grade 2 and above, G3+= grade 3 
and above. Plotted and analyzed data included only studies with relevant information 
provided. The error bars show the range of the data.
A: Age and G2+ RILT (P= 0.045).
B: Tumor size (the largest dimension) and G2+ RILT (P= 0.049).
C: Tumor size (the largest dimension) and G3+ RILT (P= 0.001).
D. Tumor location and G2+ RILT (P= 0.13).
E. Median GTV with G2+ RILT (P= 0.11).
F: Median PTV with G2+ RILT (P= 0.21).
G: Forest plot for RILT between male and female (P= 0.44).
H: Forest plot for RILT between different tumor locations (centrally vs peripherally located) 
(P= 0.65).
I: Forest plot for RILT between stage IA and IB (P< 0.001).
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Fig. 4. Dosimetric factors and RILT
This figure shows G2+ RILT rates versus BED10 (A), whole lung MLD (B) and V20 (C) of 
individual studies, and dosimetric comparisons between G2+RILT of limited studies 
provided detailed breakdown dosimetric data: MLD of the whole lung (D), MLD of 
ipsilateral lung (E), and V20 (F). BED10=biologically effective dose of using alpha/beta of 
10. MLD= Mean Lung Dose; V20= volume at and above 20 Gy; RILT= radiation induced 
lung toxicity.
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